Home Psoriasis CMHP recommends approval for Janssen’s mAb in psoriatic arthritis

CMHP recommends approval for Janssen’s mAb in psoriatic arthritis


The approval means the drug could be used for the treatment of adult patients with active psoriatic arthritis and applies only to the European Union (EU). Currently, guselkumab is approved in the EU to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Guselkumab selectively binds to the p19 subunit of interleukin 23 (IL-23 ) and inhibits its interaction with the IL-23 receptor, which contributes to the pathogenesis of inflammatory diseases such as psoriatic arthritis.

CHMP’s recommendation is based on data from the phase III clinical trials Discover-1 and Discover-2 that demonstrated the efficacy and safety of guselkumab at 100 mg q4w and q8w for psoriatic arthritis patients.

Guselkumab is currently approved in the U.S., Canada, Japan, Brazil, and Ecuador for the treatment of adults with active psoriatic arthritis. The European Commission is expected to make a final decision regarding the drug’s expansion later this year, Janssen said.

Related Reading

J&J’s Ebola vaccine approved by EU
Johnson & Johnson announced that the European Commission granted marketing authorization for its Janssen Pharmaceutical Ebola vaccine regimen for…

Copyright © 2020 scienceboard.net


This site uses Akismet to reduce spam. Learn how your comment data is processed.